2. UroToday Home
  3. Video Lectures

Precision Medicine in Prostate Cancer

PTEN Loss and the Future of Precision Treatment in mHSPC - Karim Fizazi & Noel Clarke
Implementing Systemic Biomarker Testing for Metastatic Prostate Cancer Patients - Pedro Barata
AMPLITUDE Trial: Niraparib Delays Progression in HRR-Mutant Prostate Cancer - Gerhardt Attard
Lutetium-177 PSMA Radioligand Therapy Advances to Earlier mCRPC Setting - Daniel Petrylak & Steven Finkelstein
TRITON3 Final Overall Survival Results for Rucaparib in BRCA-Mutated Prostate Cancer - Alan Bryce
Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor
Underutilization of Genomic Testing in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata
Lutetium PSMA Therapy in mCRPC: Real-World Evidence from PRECISION Data Platform - Oliver Sartor
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
Exploring Actinium-225 in PSMA-Targeted Therapy for Prostate Cancer - Michael Morris
ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor
Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs
RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar
PARP Inhibitors in Prostate Cancer Challenges and Opportunities in Clinical Practice "Discussion"
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
Exploring Actinium-225: Transforming Cancer Treatment with Targeted Radiopharmaceuticals - John Valliant
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor
Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer - Nima Sharifi
NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg
AMG 509's Potential in Prostate Cancer Therapy - Michael Morris
Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard
Influencing Best Practices for Genomic and Germline Testing in Urology - Abhishek Srivastava
Loss of SYNCRIP Unleashes APOBEC-Driven Mutagenesis, Tumor Heterogeneity and AR-Targeted Therapy Resistance in Prostate Cancer - Ping Mu
Understanding the Underutilization of Germline Genetic Testing in Prostate Cancer - Sarah Young & David Wise
Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study - Fatima Karzai & Rana McKay
Exploring the Clinical Trial Landscape for Metastatic Castration-Resistant Prostate Cancer: Insights on Genetic Testing, Radiopharmaceuticals, and Promising Trials - Elena Castro
Challenges, Controversies, and Opportunities of PARP Inhibitor Combinations with Androgen Receptor Signaling Inhibitors - Kim Chi
Interim Overall Survival Analysis of TRITON3: Rucaparib vs Physician's Choice of Therapy in mCRPC with Homologous Recombination Deficiency - Alan Bryce
Overview of the Decipher® Genomic Classifier
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
Clinically Relevant Biomarkers in Castration-Resistant Prostate Cancer - Noel Clarke
Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor
From Blood to Diagnosis: the Role of ctDNA in Prostate Cancer Treatment - Alexander Wyatt
Advances in Liquid Biopsies for Guiding Cancer Therapy - Jeffrey Ross
Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce
rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC - Fred Saad
PROCLAIM Study Reveals Impact of Germline Genetic Testing on Prostate Cancer Clinical Decisions - Neal Shore
Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network, 2021 PCF-Pfizer Global Health Equity Challenge Award - Veda Giri
BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor
Incorporating Molecular Testing into Clinical Practice for Prostate Cancer - Elena Castro & Colin Pritchard
Fast Facts: The Importance of Genetic Testing in Prostate Cancer - Brittany Szymaniak
Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley
Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain
Integrating Germline and Somatic Mutations Tests into Clinical Practice Workflows - Wassim Abida
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
Integrating Genetics and Genomics into Treatment Decisions for Men with Prostate Cancer - Panagiotis Vlachostergios
Personalized Approaches to the Treatment of Prostate Cancer - Kenneth Pienta and James Gulley
Implementation of Germline Testing for Prostate Cancer - Veda Giri
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
PARP Inhibition in Castration-Resistant Prostate Cancer - Daniel Petrylak
PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study
Genetically Informed Treatment for Advanced and Metastatic Prostate Cancer - Alicia Morgans
PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain
Role of PARP Inhibitors in Prostate Cancer - Evan Yu
Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce